<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Adriano Aguzzi</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Zurich</td>
</tr>
<tr>
<td class="label">Country</td>
<td>Switzerland</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-5988-6783" target="_blank">0000-0001-5988-6783</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Prion diseases, [Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Prions, [Neuroinflammation](/mechanisms/neuroinflammation)</td>
</tr>
</table>
Adriano Aguzzi
Overview
Adriano Aguzzi is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Zurich. Their research focuses on Prions, Neuroinflammation, with particular emphasis on Prion diseases and Alzheimer's Disease. With an h-index of 200, Aguzzi is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Adriano Aguzzi</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Zurich</td>
</tr>
<tr>
<td class="label">Country</td>
<td>Switzerland</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-5988-6783" target="_blank">0000-0001-5988-6783</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Prion diseases, [Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Prions, [Neuroinflammation](/mechanisms/neuroinflammation)</td>
</tr>
</table>
Adriano Aguzzi
Overview
Adriano Aguzzi is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Zurich. Their research focuses on Prions, Neuroinflammation, with particular emphasis on Prion diseases and Alzheimer's Disease. With an h-index of 200, Aguzzi is among the most cited researchers in the neuroscience field[@orcid2026].
Aguzzi's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Prion diseases and Alzheimer's Disease. Their research group has made significant contributions to the fields of Prions, Neuroinflammation, publishing in high-impact journals including leading neuroscience journals.
Based at University of Zurich, Aguzzi collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- Prion diseases
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Mechanisms of Interest
- Prions
- [Neuroinflammation](/mechanisms/neuroinflammation)
Programmatic Emphasis
Aguzzi's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Prion diseases and Alzheimer's Disease[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant[@leng2021].
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Prions, Neuroinflammation domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[PubMed author search for Adriano Aguzzi](https://pubmed.ncbi.nlm.nih.gov/?term=Adriano+Aguzzi%5BAuthor%5D)[@orcid2026]
[Google Scholar author search for Adriano Aguzzi](https://scholar.google.com/scholar?q=author%3A%22Adriano+Aguzzi%22)[@orcid2026]
[Semantic Scholar profile search for Adriano Aguzzi](https://www.semanticscholar.org/search?q=Adriano+Aguzzi)[@orcid2026]
Recent Research
Recent PubMed-indexed publications (2024-present):
[Structure-function relationship of alpha-synuclein fibrillar polymorphs derived from distinct synucleinopathies.](https://pubmed.ncbi.nlm.nih.gov/41814068/). Molecular systems biology. 2026.
[Lysosomal escape and TMEM106B fibrillar core determine TDP-43 seeding outcomes.](https://pubmed.ncbi.nlm.nih.gov/41497595/). bioRxiv : the preprint server for biology. 2025.
[Prime editing of the β(1) adrenoceptor in the brain restores physiological REM sleep in a mouse model of Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/41365977/). Nature communications. 2025.
[Mutual reinforcement of lymphotoxin-driven myositis and impaired autophagy in murine muscle.](https://pubmed.ncbi.nlm.nih.gov/40853947/). Brain : a journal of neurology. 2025.
[Large-scale seroepidemiology uncovers nephro-urological pathologies in people with tau autoimmunity.](https://pubmed.ncbi.nlm.nih.gov/41296806/). PLoS biology. 2025.
[Accelerating biomedical discoveries in brain health through transformative neuropathology of aging and neurodegeneration.](https://pubmed.ncbi.nlm.nih.gov/40683248/). Neuron. 2025.
Collaborators and Research Network
[Michel Goedert](/researchers/michael-goedert)
Institutional Context
Primary institutional links: [University of Zurich](/university-of-zurich). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Prions, Neuroinflammation signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Prion diseases and Alzheimer's Disease into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0001-5988-6783](https://orcid.org/0000-0001-5988-6783)
- Google Scholar: [Search for Adriano Aguzzi](https://scholar.google.com/scholar?q=author%3A%22Adriano+Aguzzi%22)
- PubMed: [Author search for Adriano Aguzzi](https://pubmed.ncbi.nlm.nih.gov/?term=Adriano+Aguzzi%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
Unknown, ORCID profile for Adriano Aguzzi (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)
[Unknown, Leng and Edison, Neuroinflammation and microglial activation in Alzheimer disease 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33198673/)